Ernexa Therapeutics (ERNAW) Stock Analysis

What Ernexa Therapeutics does

Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis. Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.

Key metrics

ETFs linked to ERNAW

Broad-market and Healthcare sector ETFs an investor holding Ernexa Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ERNAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Ernexa Therapeutics?

Ernexa Therapeutics trades under the ticker ERNAW on NASDAQ.

Which exchange is ERNAW listed on?

ERNAW is listed on NASDAQ.

What sector does Ernexa Therapeutics operate in?

Ernexa Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ERNAW in a portfolio?

PortView shows ERNAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.